Eli Lilly Sponsors Vogue World, Raising Concerns
Eli Lilly, maker of weight‑loss drugs, backed Milan’s Vogue World, prompting backlash from eating‑disorder advocates and academics. The partnership highlights growing concerns about the fashion industry’s role in promoting thinness and the medicalisation of body image.
By Felo News Desk · Published
On Tuesday night, Milan hosted the fifth edition of Vogue World, a high‑profile event curated by Anna Wintour. While models Gigi Hadid and Jennifer Lopez stole the spotlight on the runway, the event’s most controversial element was its sponsorship roster, which included Eli Lilly, the American pharmaceutical giant behind the weight‑loss drugs Mounjaro and the Foundayo pill.
Pharma Meets Fashion
Eli Lilly’s name appeared in the event credits as one of several “fashion adjacent” sponsors. The company has previously backed other major style occasions, such as the 2025 Vogue World in Hollywood and the Met Gala livestream earlier this year, where a promotional video featured actor Patrick Schwarzenegger and fashion brand Public School.
Although the partnership did not explicitly link Mounjaro or Foundayo to the show, the association of a weight‑loss drug manufacturer with a globally recognised fashion platform has drawn sharp criticism from eating‑disorder charities and scholars. These groups argue that the fashion industry has long perpetuated thin ideals through the use of extremely slender models in shows, editorials, and advertising.
Academic and Advocacy Voices
Charlotte Markey, a psychology professor at Rutgers University and author of the The Body Image series, warned that the collaboration signals a return to “thinness as an aspirational, medically attainable goal.” She added that the blending of pharmaceutical marketing with aspirational lifestyle content could normalize the idea that medical intervention is a legitimate route to body transformation.
Lauren Downing Peters, an associate professor of fashion studies at Columbia College Chicago, noted that the sponsorship reflects how GLP‑1 medications have become embedded in both the fashion industry and wider culture. Tom Quinn, director of external affairs at the eating‑disorder charity Beat, described the partnership as “alarming” and urged both sectors to promote healthier body narratives.
Marketing Tactics and Public Response
As part of the Milan event, Vogue released a video titled “Portrait of Progress” produced in collaboration with Eli Lilly. The clip juxtaposes fashion manufacturing with pharmaceutical innovation, featuring a voiceover that claims “everything begins with health.” While the video does not mention weight‑loss drugs directly, it links health to creative freedom, a stance that critics say subtly endorses medical weight management as a lifestyle choice.
In August, the United Kingdom became the first European country to approve Eli Lilly’s weight‑loss pill, further amplifying the debate. In the United States, the company dominates the diabetes and weight‑loss drug market, holding a market share of over 60% and a valuation exceeding one trillion dollars.
Industry Trends and Size Diversity
Recent data from Vogue Business revealed a concerning trend: of the 9,038 looks presented across 198 women’swear shows in September 2025, 97.1% featured straight‑size models (US size 0‑4). Only 0.9% were plus‑size (UK 18+), and 2% were mid‑size (UK 10‑16). The prevalence of ultra‑thin models, combined with the promotion of GLP‑1 drugs for aesthetic reasons, has raised questions about the industry’s commitment to inclusivity.
While the Milan show did feature plus‑size models Paloma Elsesser and Ashley Graham, some observers felt the inclusion was performative. Felicity Hayward, a plus‑size model and advocate for size diversity, described the casting as “size diversity cosplay” and criticized the sponsorship as “advocating for thinness with a fog horn.”
Company Position and Future Outlook
According to a Condé Nast source, the partnership focused on Eli Lilly’s overall brand rather than any single product. An Eli Lilly spokesperson stated, “This sponsorship is part of our 150th anniversary—150 years of putting health above all.” The company emphasised its intent to shift the conversation about weight from aesthetics to health and to challenge the stigma faced by people with obesity.
As the debate continues, stakeholders in both fashion and pharmaceuticals are under pressure to examine the broader cultural and psychological implications of their collaborations. The question remains: can the industry reconcile its commercial interests with a genuine commitment to body positivity and health?
Key facts
- Eli Lilly sponsors Vogue World in Milan, sparking backlash
- Critics argue the partnership normalises medical weight loss as a beauty goal
- Academic voices warn of psychological impacts on audiences
- Video campaign links health to creativity, subtly endorsing pharma marketing
- Industry data shows persistent ultra‑thin model prevalence
- Plus‑size inclusion seen as performative by some advocates
Why it matters
The partnership highlights a growing trend of pharmaceutical companies embedding themselves in fashion, raising ethical concerns about normalising medical weight loss as a beauty standard and potentially influencing vulnerable audiences.
Frequently asked questions
What drugs does Eli Lilly produce that are relevant to this story?
Eli Lilly manufactures Mounjaro and the Foundayo pill, both weight‑loss medications
Why is the fashion industry criticized for promoting thinness?
The industry frequently uses extremely slender models, reinforcing unrealistic body ideals that can harm body image
How did the event address the partnership with Eli Lilly?
Vogue released a video titled “Portrait of Progress” that highlighted health and innovation without directly mentioning weight‑loss drugs
Sources
- [1] theguardian.com — originally reported as “‘It’s problematic’: concern as weight-loss jab maker sponsors Vogue World event”
